home / stock / imuc / imuc quote
Last: | $0.1689 |
---|---|
Change Percent: | 45.5% |
Open: | $0.0921 |
Close: | $0.1689 |
High: | $0.1689 |
Low: | $0.0921 |
Volume: | 10,100 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.1689 | $0.0921 | $0.1689 | $0.1689 | $0.0921 | 10,100 | 07-19-2024 |
$0.169 | $0 | $0.169 | $0 | $0 | 7 | 07-18-2024 |
$0.169 | $0 | $0.169 | $0 | $0 | 75 | 07-17-2024 |
$0.169 | $0 | $0.169 | $0 | $0 | 4 | 07-16-2024 |
$0.169 | $0.169 | $0.169 | $0.169 | $0.169 | 142 | 07-15-2024 |
$0.169 | $0.1699 | $0.169 | $0.1699 | $0.083 | 2,301 | 07-12-2024 |
$0.095 | $0.1 | $0.095 | $0.1 | $0.091 | 455 | 07-11-2024 |
$0.17 | $0 | $0.17 | $0 | $0 | 3 | 07-10-2024 |
$0.17 | $0 | $0.17 | $0 | $0 | 75 | 07-09-2024 |
$0.17 | $0.111 | $0.17 | $0.17 | $0.111 | 300 | 07-04-2024 |
$0.17 | $0.111 | $0.17 | $0.17 | $0.111 | 300 | 07-03-2024 |
$0.1726 | $0.083 | $0.1726 | $0.1726 | $0.083 | 327 | 07-02-2024 |
$0.1726 | $0.1 | $0.1726 | $0.1726 | $0.1 | 255 | 07-01-2024 |
$0.1727 | $0 | $0.1727 | $0 | $0 | 3 | 06-28-2024 |
$0.1727 | $0 | $0.1727 | $0 | $0 | 5 | 06-27-2024 |
$0.1727 | $0.0821 | $0.1727 | $0.1727 | $0.0821 | 9,151 | 06-26-2024 |
$0.1728 | $0 | $0.1728 | $0 | $0 | 131 | 06-25-2024 |
$0.1728 | $0.102 | $0.1728 | $0.1729 | $0.1 | 10,523 | 06-24-2024 |
$0.19 | $0.1201 | $0.19 | $0.19 | $0.1 | 15,005 | 06-21-2024 |
$0.19 | $0.1122 | $0.19 | $0.19 | $0.072 | 12,046 | 06-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
ImmunoCellular Therapeutics Ltd. Company Name:
IMUC Stock Symbol:
OTCMKTS Market:
ImmunoCellular Therapeutics Ltd. Website:
EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613 PR Newswire MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug...
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil PR Newswire Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , ...
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology indu...